The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy

被引:0
|
作者
Liu, Tao [1 ]
Zhou, Ping [2 ]
Jiang, Xin [3 ]
Wang, Na [1 ]
Shou, Jialing [1 ]
Fang, Yuqiang [1 ,4 ]
机构
[1] Army Med Univ, Chongqing Inst Cardiol, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China
[2] First Peoples Hosp Chongqing Liang Jiang New Area, Dept Cardiol, Chongqing 401121, Peoples R China
[3] Peoples Hosp Chongqing Da Du Kou Area, Dept Cardiol, Chongqing, Peoples R China
[4] Army Med Univ, Dept Cardiol, Chongqing Inst Cardiol, Daping Hosp, 10 Changjiang Branch Rd, Chongqing 400042, Peoples R China
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2023年 / 28卷 / 01期
基金
中国国家自然科学基金;
关键词
Angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; beta-blockers; dilated cardiomyopathy; PREDICTORS; THERAPY; PREVALENCE; RECOVERY; INSIGHTS;
D O I
10.4103/jrms.jrms_626_21
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Whether combination administration of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and beta-blockers (BBs) has a "reversal" effect on cardiac structure and function for first-diagnosed idiopathic dilated cardiomyopathy (FSIDCM) patients with unclear etiologies and inducements is unknown. Materials and Methods: We studied the effect of the protocol on FSIDCM patients. The effect was investigated in 26 FSIDCM patients. The criteria of "complete reversal" included left ventricular end-diastolic diameter (LVEDD)<= 50 mm for females or <= 55 mm for males and left ventricular ejection fraction (LVEF) >= 45%; the criteria of "partial reversal" was the decreased rate of LVEDD (Delta LVEDD) >10% or the increase rate of LVEF (Delta LVEF) >10%; the criteria of "no reversal" included LVEDD >50 mm for females or >55 mm for males and Delta LVEDD <10%, and LVEF <45% and Delta LVEF <10%. Results: Within the follow-up period, nine patients showed "complete reversal," eight "partial reversal," and nine "no reversal." Improvements in echocardiogram parameters were the most significant in "complete reversal" patients (P < 0.001), followed by "partial reversal" and "no reversal" patients (P < 0.05). The QRS (Q wave, R wave, S wave) duration and symptoms duration in "complete reversal" patients were the shortest, followed by "partial reversal" and "no reversal" patients. Conclusion: ACEIs or ARBs and BBs have a "complete reversal" effect on the left ventricular size and function of some FSIDCM patients. Patients with a narrow QRS and short symptom duration may have a good response.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Treatment for diabetic nephropathy: Angiotensin receptor blockers preferred to angiotensin-converting enzyme inhibitors
    Harman-Boehm, I
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2004, 6 (05): : 296 - 298
  • [32] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Sepetavc, Filip
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    CALCIFIED TISSUE INTERNATIONAL, 2022, 111 (04) : 396 - 408
  • [33] The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis
    Song, Taejong
    Choi, Chel Hun
    Kim, Mi Kyoung
    Kim, Mi-La
    Yun, Bo Seong
    Seong, Seok Ju
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2017, 26 (01) : 78 - 85
  • [34] Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Early Period after Kidney Transplantation
    Orlic, Lidija
    Mikolasevic, Ivana
    Sladoje-Martinovic, Branka
    Bubic, Ivan
    Pavletic-Persic, Martina
    Racki, Sanjin
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 (03) : 809 - 814
  • [35] Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
    Kara L. Holloway-Kew
    Amelia G. Betson
    Kara B. Anderson
    Filip Sepetavc
    James Gaston
    Mark A. Kotowicz
    Wan-Hui Liao
    Maciej Henneberg
    Julie A. Pasco
    Calcified Tissue International, 2022, 111 : 396 - 408
  • [36] Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?
    Ong, Hean Teik
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2009, 22 (06) : 686 - 697
  • [37] Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits
    Pucci, Mark
    Sarween, Nadia
    Knox, Ellen
    Lipkin, Graham
    Martin, Una
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2015, 8 (02) : 221 - 231
  • [38] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
    Maximilian Tscharre
    Patricia P. Wadowski
    Constantin Weikert
    Joseph Pultar
    Beate Eichelberger
    Simon Panzer
    Thomas Gremmel
    Cardiovascular Drugs and Therapy, 2021, 35 : 1183 - 1190
  • [39] Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the mortality in sepsis: A meta-analysis
    Yang, Deng-Can
    Xu, Jian
    Jian, Li
    Yu, Yi
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (36)
  • [40] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
    Tscharre, Maximilian
    Wadowski, Patricia P.
    Weikert, Constantin
    Pultar, Joseph
    Eichelberger, Beate
    Panzer, Simon
    Gremmel, Thomas
    CARDIOVASCULAR DRUGS AND THERAPY, 2021, 35 (06) : 1183 - 1190